MOMotoyuki Otsuka

Motoyuki Otsuka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Motoyuki Otsuka has a total of 754 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuhiko Koike

    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    62 shared publications
  • Masao Omata

    Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi-cho, Kofu-shi, Yamanashi-Prefecture 400-8506, Japan

    53 shared publications
  • Takahiro Kishikawa

    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    39 shared publications
  • Motoko Ohno

    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    29 shared publications
  • Naoya Kato

    Unit of Disease Control Genome Medicine, The Institute of Medical Science The University of Tokyo Tokyo Japan

    26 shared publications
  • Takeshi Yoshikawa

    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    26 shared publications

Latest Publications

  • Open Access

    Segment‐Specific Occlusion of Retrieved Plastic Biliary Stents: Direct Quantification and Microbial and Material Determinants

    by Akihiro Matsumi, Kazuyuki Matsumoto, Kentaro Oki, Satoshi Kajitani, Ryosuke Sato, Tatsuya Kikuchi, Kazuya Miyamoto, Hiroyuki Terasawa, Yuki Fujii, Daisuke Uchida, et al.

    Objectives: Plastic stents (PS) are widely used for biliary drainage, with occlusion mainly caused by biofilm formation and sludge accumulation. However, direct evaluation of luminal occlusion remains limited, and its spatial distribution is poorly understood. This study aimed to quantify luminal occlusion in retrieved PS and identify associated factors. Methods: In this prospective observational study, 64 patients (196 stents) undergoing scheduled PS exchange at approximately 3‐month intervals were included. Retrieved stents were divided into proximal, central, and distal segments, and occlusion was quantified using ImageJ. Clinical, microbiological, and device‐related variables were analyzed. Multivariable linear regression was used to identify independent factors associated with occlusion. Results: The mean occlusion rate was 28.8% ± 29.8%. Occlusion was significantly higher in the proximal segment than in the central and distal segments (35.5% vs. 25.8% and 25.0%; p < 0.05). Multivariable analysis showed that age > 65 years (β = 11.62, p = 0.006), Enterococcus‐positive bile culture (β = 16.00, p = 0.012), and probiotic use (β = 14.91, p = 0.007) were independently associated with increased occlusion. Stent brand was also associated with the degree of occlusion. Conclusions: Plastic stent occlusion is segment‐dependent, predominantly affecting the proximal portion, and is associated with microbiological and material‐related factors. Direct quantification may help optimize stent design and management.

  • Open Access

    Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

    by Yuichi Honma, Shigeo Shimose, Takanori Ito, Issei Saeki, Joji Tani, Takanori Matsuura, Tetsu Tomonari, Yasuto Takeuchi, Nobuhito Taniki, Kyo Sasaki, et al.

    Background: Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes. Methods: In this multicenter retrospective study, we evaluated 299 patients with advanced HCC to assess whether early changes in peripheral blood lymphocyte counts predict clinical outcomes during Dur/Tre therapy. Changes in lymphocyte counts at 2 weeks after treatment initiation (2w‐Δlymphocyte) were analyzed in relation to objective response rate (ORR), progression‐free survival (PFS), and overall survival. Results: Patients with a high‐2w‐Δlymphocyte (> +107/μL) demonstrated a significantly higher ORR (29.6% vs. 14.0%, p < 0.001) and longer PFS (4.3 vs. 2.8 months, p = 0.035) compared with those with a low‐2w‐Δlymphocyte (≤ +107/μL). Subgroup analyses showed that higher 2w‐Δlymphocyte values were associated with better PFS across modified albumin–bilirubin grades ( p = 0.011), Barcelona Clinic Liver Cancer stages ( p = 0.007), and baseline lymphocyte‐to‐monocyte ratio ( p < 0.001). Conclusions: Early increases in peripheral blood lymphocyte counts, particularly 2w‐Δlymphocyte, may be associated with treatment response to Dur/Tre and provide complementary dynamic information to established prognostic factors. Although a favorable association with PFS was observed, this association was attenuated after propensity score matching. Further prospective studies are warranted to validate the clinical utility of 2w‐Δlymphocyte.


  • Open Access

    Atezolizumab–bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial

    by Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Tetsuya Yasunaka, et al.

  • Transabdominal ultrasonography for small-bowel lesions in Crohn’s disease: a prospective comparison with balloon-assisted enteroscopy

    by Masahiro Takahara, Sakiko Hiraoka, Keiko Takeuchi, Kensuke Takei, Toshihiro Inokuchi, Yuki Aoyama, Shoko Igawa, Mikako Ishiguro, Junki Toyosawa, Yasushi Yamasaki, et al.

  • Gel Immersion Improves Visualization in Underwater Endoscopic Mucosal Resection for Colorectal Lesions: A Prospective Crossover Trial

    by Junki Toyosawa, Yasushi Yamasaki, Hidetaka Mizushima, Mikako Ishiguro, Takashi Yamamoto, Yuki Aoyama, Keiko Takeuchi, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, et al.

    Objective: Underwater endoscopic mucosal resection (UEMR) is widely used for colorectal polyp resection, but visualization may be impaired with poor bowel preparation. Gel‐immersion endoscopy has been proposed to enhance image clarity. In this study, digital image analysis was applied to quantitatively compare lesion visibility during UEMR with water or gel immersion. Methods: In this prospective, randomized crossover trial, patients with non‐pedunculated colorectal adenomatous lesions measuring 6–19 mm were sequentially examined with water and gel immersion using white light imaging (WLI), blue laser imaging (BLI), and linked color imaging (LCI). The primary endpoint was the color difference (ΔE) between the lesion and surrounding mucosa, calculated using the Commission Internationale d'Eclairage (CIE) L*a*b* color space. Visibility scores were assessed by blinded expert endoscopists (jRCTs062220033). Results: In total, 72 lesions (median size, 8 mm) were analyzed. ΔE values were significantly greater with gel than water immersion in both WLI ( p = 0.03) and BLI ( p = 0.03), but not in LCI ( p = 0.10). The improvement in ΔE values with gel immersion was more pronounced under poor bowel preparation. Visibility scores were significantly higher with gel immersion in both WLI and BLI overall and under poor bowel preparation, whereas no significant differences were observed under good bowel preparation. Conclusion: Gel immersion significantly improves colorectal lesion visibility during UEMR, particularly under poor bowel preparation and with WLI or BLI. This technique may serve as a valuable adjunct to enhance diagnostic and therapeutic precision in challenging endoscopic conditions.


  • Open Access

    Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

    by Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, et al.

    Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related events and improving long‐term outcomes. This guideline summarizes current evidence and provides practical recommendations for the diagnosis, risk stratification, and management of MASLD in clinical practice. These recommendations were developed through systematic evaluation of the literature and expert consensus. Diagnostic approaches, including noninvasive fibrosis assessment tools, imaging, biochemical testing, and indications for referral to gastroenterology/hepatology specialists, were reviewed. Advanced fibrosis is the major determinant of liver‐related morbidity and mortality in MASLD. The Fibrosis‐4 (FIB‐4) index is a widely accessible and reliable first‐line noninvasive tool for fibrosis risk stratification. Patients with elevated FIB‐4 values or clinical features suggestive of progressive liver injury should undergo secondary assessment with elastography and be referred to a specialist when appropriate. Liver biopsy is not routinely required for the diagnosis of MASLD but remains essential for establishing a definitive diagnosis of at‐risk metabolic dysfunction–associated steatohepatitis (MASH), assessing inflammatory activity, resolving discrepancies between noninvasive tests, and differentiating MASLD from other chronic liver diseases. Lifestyle modification remains the foundation of management, with pharmacological therapy considered for patients with a high likelihood of at‐risk MASH. MASLD represents a heterogeneous disease spectrum in which advanced fibrosis is the key prognostic factor. These guideline recommendations aim to standardize clinical practice and support evidence‐based management of MASLD in Japan.


  • Open Access

    Long-Term Outcomes of Endoscopic Ultrasound-Guided Gallbladder Drainage for Acute Cholecystitis in Non-Surgical Candidates: A Multicenter Retrospective Study

    by Kei Harada, Kazuya Miyamoto, Kazuyuki Matsumoto, Kosaku Morimoto, Eijiro Ueta, Yutaka Akimoto, Nao Hattori, Taisuke Obata, Ryosuke Sato, Akihiro Matsumi, et al.

    Background/Objectives: Endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) is a minimally invasive alternative for managing acute cholecystitis in patients who are unsuitable for surgery. Although its short-term efficacy is well-established, its long-term outcomes, especially in patients with malignancy-associated cholecystitis, remain unclear. Methods: This multicenter, retrospective study included 139 patients who underwent EUS-GBD with a plastic stent for inoperable acute cholecystitis between January 2010 and October 2023. Patients were divided into two groups: a malignant group (n = 60) with cystic duct obstruction caused by cancer invasion or self-expandable metal stents, and a benign group (n = 79) with calculous or acalculous cholecystitis. The outcomes assessed included cholecystitis recurrence, time to recurrence, adverse events, and risk factors for recurrence. Results: Technical success was achieved in all patients, with an overall clinical success rate of 94.6%. Cholecystitis recurred significantly more frequently in the malignant group than in the benign group (13.3% vs. 2.5%; p = 0.015). Univariate analysis identified malignancy as a significant risk factor of recurrence (odds ratio, 5.92; p = 0.028). Conclusions: EUS-GBD is a safe and effective long-term treatment for cholecystitis in non-surgical candidates. However, malignancy-associated cholecystitis carries a high risk of recurrence, warranting careful follow-up and individualized management.


  • Open Access

    Feasibility of Comprehensive Genomic Profiling for Biliary Tract Cancer Using Transpapillary Biopsy Samples: A Prospective Study

    by Kazuya Miyamoto, Kazuyuki Matsumoto, Toshiaki Ohara, Masayoshi Fujisawa, Hirohumi Inoue, Ryosuke Sato, Akihiro Matsumi, Yuki Fujii, Daisuke Uchida, Motoyuki Otsuka

    Background: Patients with biliary tract cancer (BTC) often have actionable mutations, and comprehensive genomic profiling (CGP) plays an important role. However, the feasibility of CGP using transpapillary biopsy (TPB) samples remains unclear. Methods: Thirty patients with suspected BTC based on radiographic imaging were enrolled. Pre‐analytical criteria for CGP suitability were based on the OncoGuide NCC Oncopanel System (NCCOP) and FoundationOne CDx (F1CDx). Each patient underwent six biopsies using an endoscopic introducer: five biopsy samples were preserved as formalin‐fixed paraffin‐embedded (FFPE) samples and one as a fresh frozen (FF) sample. DNA quality indicators were compared between the two groups. Results: Malignancy was confirmed in 29 patients, and one had a benign biliary stricture. Suitability rate was 31% (9/29) for NCCOP and 3.4% (1/29) for F1CDx. Compared to FFPE samples, FF samples demonstrated significantly higher DNA concentration [ng/μL, interquartile range (IQR)], [0.34 (0.16–0.95) vs. 37.8 (11.6–67.6), p < 0.001] and DNA integrity number (IQR) [7.1 (6.8–7.3) vs. 8.9 (8.3–9), p = 0.021]. Conclusions: Introducer‐assisted multipass TPB may increase the rate of obtaining adequate CGP specimens, but its suitability remains limited and strongly panel dependent. Since FF samples have better DNA quality, establishing a system detailing their use is desirable. Trial Registration: ClinicalTrials.gov identifier: UMIN 000049826


  • Open Access

    Hepatocellular carcinoma in Fontan-associated liver disease: Incidence, risk stratification, and surveillance implications

    by Hideki Onishi, Norihisa Toh, Kenji Baba, Yasuhiro Kotani, Shingo Kasahara, Motoyuki Otsuka

    Background: Hepatocellular carcinoma (HCC) is a serious complication of Fontan-associated liver disease (FALD). However, data on its incidence, risk factors, and outcomes in this rare population are limited. We aimed to assess the incidence and predictors of HCC and evaluate the utility of surveillance in patients with FALD. Methods: We conducted a retrospective cohort study on patients with FALD who were referred to our gastroenterology department. The cumulative incidence of HCC after FALD diagnosis was calculated, and multivariate analysis was used to identify independent risk factors. Overall survival after FALD diagnosis was compared between patients who developed HCC and those who did not. Results: A total of 120 patients with FALD were followed up for a median period of 50.0 months. The cumulative incidence rates of HCC at 1, 2, and 3 years after FALD diagnosis were 0.9%, 2.7%, and 3.9%, respectively. Elevated alpha-fetoprotein (AFP) at FALD diagnosis was independently associated with HCC development (hazard ratio, 1.29; 95% confidence interval, 1.04–1.60; p =0.01). There was no significant difference in overall survival between patients with and without HCC in this cohort (log-rank test, p =0.50). Conclusions: Patients with FALD face a non-negligible risk of developing HCC, thus supporting the need for surveillance. Elevated AFP levels at the time of FALD diagnosis may aid in risk stratification, which enables the targeted monitoring and early detection of HCC. Furthermore, routine surveillance contributes to the excellent prognosis of patients with FALD who develop HCC, thus making their prognosis comparable to that of patients without HCC.


  • Open Access

    Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

    by Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Hideki Onishi, Miwa Kawanaka, Akinobu Takaki, Kazuhiro Nouso, Kazuya Kariyama, Shinichiro Nakamura, et al.

    Background: Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline resectable (BR) classification combined with the barcelona clinic liver cancer (BCLC) staging system to identify patients most likely to benefit from conversion following atezolizumab plus bevacizumab (ATZ/BEV) therapy. Methods: In this multicenter retrospective study, 532 patients with unresectable HCC treated with ATZ/BEV were categorized using the BR classification and stratified according to the BCLC stage. We evaluated objective response rate (ORR), conversion rate, and overall survival (OS) and carried out multivariate logistic regression analysis to identify predictors of conversion. Results: Conversion therapy was performed in 5.9% of patients. Among those with BCLC‐C HCC, the conversion rate was significantly higher in BR1 HCC than in BR2 HCC (15.2% vs. 2.0% and p < 0.01), and BR1 status was independently associated with conversion (odds ratio 7.0). Patients with BCLC‐C/BR1 staging showed the highest ORR (45.0%) and favorable OS after conversion ( p = 0.015). In contrast, the BR classification had limited predictive value in patients with BCLC‐B HCC. Notably, downstaging from BR1 to resectable status was more common than from BR2, suggesting higher conversion feasibility. Conclusions: Integrating BR classification with BCLC staging identified BCLC‐C/BR1 patients as optimal candidates for conversion therapy after ATZ/BEV treatment. These findings support incorporating anatomical and oncological criteria into systemic strategies to enable curative interventions in advanced HCC.